Mycophenolate mofetil (MMF) is an immunosuppressive agent used in transplantation, with evidence of superior protection against acute transplant rejection compared to azathioprine-containing regimens. Subsequently MMF has been used in a variety of autoimmune conditions. The major experience in systemic lupus erythematosus (SLE) has focused on proliferative lupus nephritis. Following its success in the treatment of lupus nephritis, MMF is now being used to control other SLE manifestations such as, lupus disease activity, haematological manifestations and resistant skin lupus. In this review, we discuss our own experience and the literature report about the use of MMF in SLE.
WarrensAN.The evolving role of mycophenolate mofetil in renal transplantation.QJM2000; 93: 15–20.
2.
ModerKG.Mycophenolate mofetil: new applications for this immunosuppressant.Ann Allergy Asthma Immunol2003; 90: 15–19; quiz 20, 78.
3.
GaubitzM, SchoratA, SchotteH, KernP, DomschkeW.Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial.Lupus1999; 8: 731–736.
4.
ChanTM, LiFK, TangCS. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.N Engl J Med2000; 343: 1156–1162.
KarimMY, AlbaP, CuadradoMJ. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents.Rheumatology (Oxford)2002; 41: 876–882.
7.
AlbaP, KarimMY, HuntBJ.Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome.Lupus2003; 12: 633–635.
8.
SchanzS, UlmerA, RassnerG, FierlbeckG.Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil.Br J Dermatol2002; 147: 174–178.
9.
AduD, CrossJ, JayneDR. Treatment of systemic lupus erythematosus with mycophenolate mofetil.Lupus2001; 10: 203–208.
10.
DooleyMA, CosioFG, NachmanPH. Mycophenolate mofetil therapy in lupus nephritis: clinical observations.J Am Soc Nephrol1999; 10: 833–839.
11.
Ginzler EMAC, BuyonJ, DooleyMA. A multicenter study of mycophenolate mofetil (MMF) vs. intravenous cyclophosphamide (IVC) as induction therapy for severe lupus nephritis (LN): preliminary results (abstract).Arthritis Rheum2003; 49: S647.
HanjaniNM, NousariCH.Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement.Arch Dermatol2002; 138: 1616–1618.
16.
GoyalS, NousariHC.Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil.J Am Acad Dermatol2001; 45: 142–144.
17.
GelberAC, NousariHC, WigleyFM.Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases.J Rheumatol2000; 27: 1542–1545.
18.
SamadAS, LindsleyCB.Treatment of pulmonary hemorrhage in childhood systemic lupus erythematosus with mycophenolate mofetil.South Med J2003; 96: 705–707.
RiskallaMM, SomersEC, FaticaRA, McCuneWJ.Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus.J Rheumatol2003; 30: 1508–1512.
21.
European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV. 10. Pregnancy in renal transplant recipients.Nephrol Dial Transplant2002; 17(Suppl. 4): 50–55.
